Mobile

A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 mo...

Update Il y a 5 ans
Reference: EUCTR2005-000380-26

A 12 month, multicenter, randomized, parallel, open-label study, to evaluate renal function and efficacy of Certican® (everolimus) with Simulect® (basiliximab) and cyclosporine discontinuation at 3 month post-transplant vs minimization, in de novo kidney transplant recipients

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective is to compare renal function in the two treatment groups at month 12 post-transplant, as measured by calculated GFR (Nankivell), serum creatinine and calculated creatinine clearance (Cockroft- Gault). Intra-group change in GFR , as determined by Nankivell’s formula, and the GFR’s slope in the period between visits 6 and 12 months will also be determined.

Inclusion criteria

  • Renal transplant

Links